Palvella Therapeutics, Inc. (PVLA) – What Are Investment Firms Thinking About This Stock?

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have earned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $209.79.

PVLA has been the subject of a number of recent research reports. Truist Financial set a $207.00 price objective on Palvella Therapeutics in a research note on Wednesday, August 5th. Raymond James Financial set a $226.00 target price on Palvella Therapeutics in a research note on Friday. HC Wainwright restated a “buy” rating on shares of Palvella Therapeutics in a research report on Tuesday. Chardan Capital began coverage on shares of Palvella Therapeutics in a report on Monday, September 21st. They issued a “buy” rating and a $240.00 price objective on the stock. Finally, William Blair began coverage on shares of Palvella Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock.

Insider Activity at Palvella Therapeutics

In other news, Director Christopher P. Kiritsy sold 313 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the completion of the sale, the director owned 250 shares in the company, valued at $39,250. This represents a 55.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director George M. Jenkins sold 7,174 shares of the company’s stock in a transaction dated Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total transaction of $935,202.64. Following the completion of the sale, the director directly owned 139,790 shares of the company’s stock, valued at $18,223,024.40. The trade was a 4.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 56,743 shares of company stock worth $8,219,632 over the last ninety days. 17.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC raised its holdings in shares of Palvella Therapeutics by 38.3% during the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after acquiring an additional 271,617 shares during the period. BlackRock Inc. purchased a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at approximately $140,343,000. Jennison Associates LLC boosted its stake in Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock worth $79,852,000 after purchasing an additional 253,128 shares during the period. Siren L.L.C. boosted its stake in Palvella Therapeutics by 243.3% in the 1st quarter. Siren L.L.C. now owns 257,485 shares of the company’s stock worth $32,096,000 after purchasing an additional 182,485 shares during the period. Finally, Primecap Management Co. CA acquired a new position in Palvella Therapeutics in the 2nd quarter worth approximately $39,150,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Trading Up 0.8%

Shares of NASDAQ:PVLA opened at $123.92 on Wednesday. The firm has a market cap of $1.79 billion, a PE ratio of -25.66 and a beta of -0.27. The company has a fifty day simple moving average of $144.25 and a 200 day simple moving average of $134.51. Palvella Therapeutics has a 12-month low of $68.96 and a 12-month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). As a group, equities research analysts forecast that Palvella Therapeutics will post -6.41 EPS for the current fiscal year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.